

# Automatic prostate cancer detection through DCE-MRI images: all you need is a good normalization

Guillaume Lemaître<sup>a,b,\*</sup>, Robert Martí<sup>b</sup>, Fabrice Meriaudeau<sup>a,c</sup>

<sup>a</sup>*LE2I UMR6306, CNRS, Arts et Métiers, Univ. Bourgogne Franche-Comté, 12 rue de la Fonderie, 71200 Le Creusot, France*

<sup>b</sup>*ViCOROB, Universitat de Girona, Campus Montilivi, Edifici P4, 17071 Girona, Spain*

<sup>c</sup>*CISIR, Electrical & Electronic Engineering Department, Universiti Teknologi Petronas, 32610 Seri Iskandar, Perak, Malaysia*

---

## Abstract

This template helps you to create a properly formatted L<sup>A</sup>T<sub>E</sub>X manuscript.

*Keywords:* DCE-MRI, prostate cancer, normalization, classification, quantification

---

## 1. Introduction

Prostate Cancer (PCa) is the second most frequently diagnosed men cancer, accounting for 899,000 cases leading to 258,100 deaths (Ferlay et al., 2010). As highlighted by the PI-RADS Steering Committee, the two main challenges to be  
5 addressed are (Weinreb et al., 2016): (i) the improvement of detecting clinically significant PCa and (ii) an increase of the confidence in benign or dormant cases, avoiding unnecessary invasive medical exams. In this regard, multiparametric Magnetic Resonance Imaging (MRI) (mpMRI) is frequently used to build robust Computer-Aided Detection and Diagnosis (CAD) systems to detect, localize,  
10 and grade PCa. In general, CAD systems are based on mpMRI which combines several of the following modalities (Lemaître et al., 2015): T<sub>2</sub> Weighted (T<sub>2</sub>-W)-MRI, Dynamic Contrast-Enhanced (DCE)-MRI, Apparent Diffusion Coefficient (ADC) maps, and Magnetic Resonance Spectroscopy Imaging (MRSI).

---

\*Corresponding author.

Email address: [g.lemaître58@gmail.com](mailto:g.lemaître58@gmail.com) (Guillaume Lemaître)

In DCE-MRI, a contrast media is injected intravenously and a set of images  
15 is acquired over time. Consequently, each voxel in the image is a dynamic  
signal which is related to the vascular properties of the tissue. In fact, these  
properties are automatically extracted using quantitative or semi-quantitative  
approaches (Lemaître et al., 2015).

The former group of approaches uses pharmacokinetic modelling based on a  
20 bicompartiment model, namely Brix (Brix et al., 1991) and Tofts (Tofts et al.,  
1995) models. The parameters of the Brix model are found assuming a linear  
relationship between the media concentration and MRI signal intensity. This as-  
sumption has shown, however, to lead to inaccurate parameter calculation (Heil-  
mann et al., 2006). In the contrary, Tofts model only requires a conversion from  
25 MRI signal intensity to concentration, which can become a non-linear relation-  
ship using specific equation of MRI sequences (e.g., FLASH sequence). Tofts  
modelling suffers, however, from an higher complexity (Gliozzi et al., 2011). The  
conversion using the non-linear approach requires to acquire a  $T_1$  map which  
is not always possible during clinical examination. Furthermore, the parameter  
30 calculation require the Arterial Input Function (AIF) which is challenging to  
measure and can also lead to inaccurate estimation of the parameters.

The latter group of approaches are rather mathematical than pharmacoki-  
netic modelling (Huisman et al., 2001; Gliozzi et al., 2011). These methods  
offer the advantages to not require any knowledge about the MRI sequence nor  
35 any conversion from signal intensity to concentration. However, the heuristic  
approach propose by Huisman et al. requires an estimate regarding the noise  
standard deviation of the signal as well as manual tuning.

Nevertheless, all presented methods suffer from two major drawbacks: (i)  
the inter-patient variability of the data lead to a variation of the parameters  
40 estimated and to poor classification performance while designing CAD systems,  
and (ii) only few parameters are used to characterize the dynamic signal imply-  
ing that some information are discarded.

In this work, we propose a fully automatic normalization method for DCE-  
MRI that reduce the inter-patient variability of the data. Furthermore, we show

45 that using the full normalized signal lead to the best classification performance.

The paper is organized as follows: Section 2 outlines our normalization strategy (Section 2.3) as well as specificity regarding the state-of-the-art methods used for comparison (Section 2.4). The dataset, experiments, and results are reported in Section 3 while discussed in Section 4 followed by a concluding  
50 section.

## 2. Materials and methods

### 2.1. Data

The multi-parametric MRI data are acquired from a cohort of patients with higher-than-normal level of Prostate-Specific Antigen (PSA). The acquisition  
55 is performed using a 3T whole body MRI scanner (Siemens Magnetom Trio TIM, Erlangen, Germany) using sequences to obtain T<sub>2</sub>-W-MRI, DCE-MRI and Diffusion Weighted (DW)-MRI. Aside of the MRI examination, these patients also have underwent a guided-biopsy. The dataset is composed of a total of 20 patients of which 18 patients have biopsy proven PCa and 2 patients are  
60 “healthy” with negative biopsies. Therefore, 13 patients have a PCa in the Peripheral Zone (PZ), 3 patients have PCa in the Central Gland (CG), 2 patients have invasive PCa in both PZ and CG and finally 2 patients are considered as “healthy”. An experienced radiologist has segmented the prostate organ — on T<sub>2</sub>-W- and DCE-MRI — as well as the prostate zones (i.e., PZ and CG) and  
65 PCa on the T<sub>2</sub>-W-MRI.

The DCE-MRI sequence consists in a kinetic study composed of 40 samples over time with a time resolution of 6.5 s. These DCE-MRI sequences are resampled using the spatial information of the T<sub>2</sub>-W MRI sequence with dimensions of  $448 \times 360 \times 64$  and voxel spacing of  $0.68 \times 0.68 \times 1.25$  mm<sup>3</sup>. A linear interpolation is used to compute missing data during the up-sampling. The volumes  
70 of the DCE-MRI dynamic are rigidly registered, to remove any patient motion during the acquisition. Furthermore, a non-rigid registration is performed between the T<sub>2</sub>-W- and DCE-MRI in order to propagate the prostate zones and




Figure 1: Illustration of the variations of the intensity PDF over time of two patients in a DCE-MRI.

PCa ground-truths. The resampling is implemented in C++ using the Insight  
75 Segmentation and Registration Toolkit (Ibanez et al., 2005).

## 2.2. Implementation

The implementation of the registration (C++), normalization (Python), and classification pipeline (Python) are publicly available on GitHub<sup>1</sup>. The data used for this work are also publicly available<sup>2</sup>.

## 80 2.3. Normalization of DCE-MRI images

In this work, we proposed a method to normalized DCE-MRI prostate data, although it can be ported to any DCE-MRI sequences. The aim of the method is to reduce the intra-patient variations that can occur during acquisition. In T<sub>2</sub>-W-MRI prostate image, an offset and a scale factor are the two factors driv-  
85 ing the intra-patient variation. Therefore, these variations are corrected using a  $z$ -score approach assuming that the data follow a Rician distribution (Lemaitre et al., 2016). In DCE-MRI, there is additional factors characterizing such variations. These variations can be highlighted by observing the evolution of the

---

<sup>1</sup><https://github.com/I2Cvb/lemaitre-2016-nov/tree/master>

<sup>2</sup><http://kaggle.com>




Figure 2: Illustration of the estimator found using the shortest-path through the graph.

intensity Probability Density Function (PDF) of the DCE-MRI over time, as  
 90 shown in the heatmap in Fig. 1. These variations are: (i) an offset of the peak  
 value before pre-contrast, (ii) a time offset depending of the contrast injection,  
 and (iii) a global scale factor related to the enhancement. Therefore, our normal-  
 ization method should attenuate all these variations and be performed globally  
 across the different time sequence rather than for each independent sequence.

### 95 2.3.1. Graph-based offset correction for each DCE-MRI sequence

Before to standardize each sequence, the first step of the normalization is to  
 cancel the intensity shift which is specific for each patient. The intensity PDF  
 do not follow either a Rician or Gaussian distribution over time. Therefore, the  
 mean cannot be used as a potential estimate for the offset. Additionally, this  
 100 offset should be characterized by a smooth transition over time. This problem  
 can be solved using the graph-theory: considering the intensity PDF over time  
 as shown in Fig. 1, the offset is the boundary splitting the heatmap in two  
 partitions such that it is as close as possible to the peak of the intensity PDF  
 (see Fig. 2 for an illustration). Given the heatmap, a directed weighted graph  
 105  $\mathcal{G} = (\mathcal{V}, \mathcal{E})$  is built by taking each bar of the heatmap as a node and connecting  
 each pair of bars by an edge. The edge weight  $w_{ij}$  between two nodes  $i$  and

$j$  corresponding to two pixels at position  $(x_i, y_i)$  and  $(x_j, y_j)$ , respectively, is defined as in Eq. (1):

$$w_{ij} = \begin{cases} \alpha \exp(1 - \frac{H(i)}{\max(H)}) & \text{if } x_j = x_i + 1 \text{ and } y_j = y_i \\ (1 - \alpha) \exp(1 - \frac{H(i)}{\max(H)}) & \text{if } x_j = x_i \text{ and } y_j = y_i + 1, \\ 0 & \text{otherwise} \end{cases} \quad (1)$$

where  $H$  is the heatmap,  $\alpha$  is a smoothing parameter controlling the partition-  
110 ing.


Therefore, the offset is estimated by finding the shortest-path to cross the graph using Dijkstra algorithm. The entry and exiting nodes are set to be the bin with the maximum probability for the first DCE-MRI serie and the bin corresponding to the median value for the last DCE-MRI serie, respectively. To  
115 ensure a robust estimation of the offset, the process of finding the shortest-path is iteratively repeated by shifting the data and updating the heatmap as well as the graph  $\mathcal{G}$ . The procedure is stopped once that the offset found do not change. In general, this process is not repeated more than 3 iterations. An example of the offset found using this approach is presented in Fig. 2. Finally,  
120 each sequence is shifted using this offset.

### 2.3.2. Time offset and data dispersion correction

The next variations to correct are the time offset and the data dispersion. By computing the Root-Mean-Square Deviation (RMSE) for each DCE-MRI, one can observed these two variations as shown in Fig. 3(a). Therefore, to correct  
125 these variations, we propose to register each patient RMSE to a mean model which corresponds to the mean of all patients RMSE. The parametric model to perform the registration is formulated as in Eq. (2):

$$T(\alpha, \tau, f(t)) = \alpha f(t - \tau), \quad (2)$$

where  $\alpha$  and  $\tau$  are the two parameters handling the time offset and global scale, respectively,  $f(\cdot)$  is the RMSE function.



(a) RMSE computed for each patient of our dataset. (b) RMSE after alignment using the curve parametric model.

Figure 3: Illustration of the correction of the time offset and the data dispersion.

Therefore the registration problem is equivalent to:

$$\arg \min_{\alpha, \tau} = \sum_{t=0}^N [T(\alpha, \tau, f(t)) - \mu(t)]^2, \quad (3)$$

where  $\mu(\cdot)$  is the mean model,  $N$  is the number of DCE-MRI serie.

Illustration of the correction applied to each RMSE patient is shown in Fig. 3(b). Once all these parameters have been inferred, the data can be shifted as well as scale.

## 2.4. Quantification of DCE-MRI

### 2.4.1. Brix and Hoffmann models

In the Brix model (Brix et al., 1991), the MRI signal intensity is assumed to be proportional to the media concentration. Therefore, the model is expressed as in Eq. (4):

$$s_n(t) = 1 + A \left[ \frac{\exp(k_{el}t') - 1}{k_{ep}(k_{ep} - k_{el})} \exp(-k_{el}t) - \frac{\exp(k_{ep}t') - 1}{k_{el}(k_{ep} - k_{el})} \exp(-k_{ep}t) \right], \quad (4)$$

with

$$s_n(t) = \frac{s(t)}{S_0}, \quad (5)$$

where  $s(t)$  and  $S_0$  are the MRI signal intensity at time  $t$  and the average pre-contrast MRI signal intensity, respectively;  $A$ ,  $k_{el}$ , and  $k_{ep}$  are a constant proportional to the transfer constant, the diffusion rate constant, and the rate constant, respectively. Additionally, during the injection time  $0 \leq t \leq \tau$ ,  $t' = t$  and afterwards while  $t > \tau$ ,  $t' = \tau$ .

Following this model, Hoffmann et al. propose the following similar model as expressed in Eq. (6):

$$s_n(t) = 1 + \frac{A}{\tau} \left[ \frac{k_{ep} (\exp(k_{el}t') - 1)}{k_{el}(k_{ep} - k_{el})} \exp(-k_{el}t) - \frac{\exp(k_{ep}t') - 1}{(k_{ep} - k_{el})} \exp(-k_{ep}t) \right]. \quad (6)$$

The parameters are estimated by fitting the model using non-linear least-squares optimization solved with Levenberg-Marcquardt.

#### 2.4.2. Tofts model

The extended Tofts model is formulated as in Eq. (7):

$$C_t(t) = K_{trans}C_p(t) * \exp(-k_{ep}t) + v_pC_p(t), \quad (7)$$

where  $*$  is the convolution operator;  $C_t(t)$  and  $C_p(t)$  is the concentration of contrast agent in the tissue and in the plasma, respectively;  $K_{trans}$ ,  $k_{ep}$ , and  $v_p$  are the volume transfer constant, the diffusion rate constant, and the plasma volume fraction, respectively.

Therefore, Tofts model requires to: (i) detect candidate voxels from the femoral or iliac arteries and estimate a patient-based AIF signal, (ii) convert the MRI signal intensity (i.e., AIF and dynamic signal) to a concentration, and (iii) in the case of a population-based AIF, estimate an AIF signal.

#### Segmentation of artery voxels and patient-based AIF estimation

The AIF signal from DCE-MRI can be manually estimated by selecting the most-enhanced voxels from the femoral or iliac arteries (Meng et al., 2010). Few methods have been proposed to address the automated extraction of AIF signal. Chen et al. filter successively the possible candidates (Chen






Figure 4: Illustration of the segmentation of the area used to determine the AIF.

et al., 2008): (i) dynamic signals with small peak are rejecting by thresholding, (ii) voxels with a small wash-in are rejected by thresholding, (iii) a blob detector is used and large enough regions are kept, and (iv) circular and cylindricity are used to reject the last false positive. Zhu et al. propose an iterative method selecting voxels which best fit a gamma variate function (Zhu et al., 2011). However, it requires to compute first and second derivatives as well as maximum curvature points. Shanbhag et al. propose a 4-steps algorithm (Shanbhag et al., 2012; Fennessy et al., 2015): (i) remove slices with artefacts and find the best slices based on intrinsic anatomic landmarks and enhancement characteristics, (ii) find the voxel candidates using the maximum enhanced voxels and a multi-label maximum entropy based thresholding algorithm, (iii) excluding region next to the endorectal coil, and (iv) selecting the best 5 candidates which meet enhancement characteristics and that are correlated.

All the above methods are rather complex and thus we propose a method which is based on the following simple assumptions: (i) all possible AIF signal candidates should have a similar shape, (ii) an high enhancement, and (iii) the arteries should be almost round and within a size range. Therefore, each slice is clustered into regions using K-means clustering with  $k = 6$ . The cluster with the highest enhancement—i.e. corresponding to the 90<sup>th</sup> percentile of the maximum of each dynamic signal—contain the arteries and is selected. Finally, regions with an eccentricity smaller than 0.5 and an area in the range of  $[100, 400]$  voxels are kept. Additionally,

to remove voxels contaminated by partial volume effect, only the 10% most enhanced voxels of the possible candidates are kept as proposed by (Schabel and Parker, 2008) and the average signal is computed. A summary of the different segmentation steps is presented in Fig. 4.

**Conversion of MRI signal intensity to concentration** To estimate the free parameters of the Tofts model (see Eq. (7)), the concentration  $C_t(t)$  and  $C_p(t)$  need to be computed from the MRI signal intensity and the AIF signal, respectively. This conversion is based on the equation of the FLASH sequence—see Appendix A for details—and is formulated as in Eq. (8):

$$c(t) = \frac{1}{TR \cdot r_1} \ln \left( \frac{1 - \cos \alpha \cdot S^* \frac{s(t)}{S_0}}{1 - S^* \frac{s(t)}{S_0}} \right) - \frac{R_{10}}{r_1}, \quad (8)$$

with,

$$S^* = \frac{1 - \exp(-TR \cdot R_{10})}{1 - \cos \alpha \cdot \exp(-TR \cdot R_{10})}, \quad (9)$$

where  $s(t)$  is the MRI signal,  $S_0$  is the MRI signal prior to the injection of the contrast media,  $\alpha$  is the flip angle,  $TR$  is the Repetition Time (TR),  $R_{10}$  is the pre-contrast tissue relaxation time also equal to  $\frac{1}{T_{10}}$ ,  $r_1$  is the relaxativity coefficient of the contrast agent.

$T_{10}$  can be estimated from the acquisition of a  $T_1$  map. However, this modality was not part of the clinical trial in this research and the value of  $T_{10}$  was fixed to 1600 ms for both blood and prostate as stated in the literature (Fennessy et al., 2015; De Bazelaire et al., 2004; Carr and Carroll, 2011).

**Estimation of population-based AIF** While estimating the pharmacokinetic parameters from Tofts model, the AIF concentration  $C_p(t)$  can be computed either from the patient or a population. We presented in the two previous sections the algorithms which allows to estimate the patient-based AIF concentration. To compare with the previous approach, we also computed a population-based AIF which will be also later used to compare the performance of both approaches. In that regard, the population-based

AIF was estimated as in (Meng et al., 2010) by fitting the average patient-based AIFs to the model of Parker et al. (2006) which is formulated as in Eq. (10):

$$C_p(t) = \sum_{n=1}^2 \frac{A_n}{\sigma_n \sqrt{2\pi}} \exp\left(\frac{-(t - T_n)^2}{2\sigma_n^2}\right) + \frac{\alpha \exp(-\beta t)}{1 + \exp -s(t - \tau)}, \quad (10)$$

where  $A_n$ ,  $T_n$ , and  $\sigma_n$  are the scaling constants, centers, and widths of the  $n^{\text{th}}$  Gaussian,  $\alpha$  and  $\beta$  are the amplitude and decay constant of the exponential; and  $s$  and  $\tau$  are the width and center of the sigmoid function, respectively.

205 The parameters are estimated by fitting the model using non-linear least-squares optimization solved with Levenberg-Marcquardt.

#### 2.4.3. PUN model

Glozzi et al. show that Phenomenological Universalities (PUN) approach can be used for DCE-MRI analysis (Glozzi et al., 2011). The model has been  
210 successfully used in a CAD system proposed by Giannini et al. (2015). This model can be expressed as in Eq. (11):

$$s_n(t) = \exp\left[rt + \frac{1}{\beta}(a_0 - r)(\exp(\beta t) - 1)\right], \quad (11)$$

with

$$s_n(t) = \frac{s(t) - S_0}{S_0}, \quad (12)$$

where  $s(t)$  and  $S_0$  are the MRI signal intensity at time  $t$  and the average pre-contrast MRI signal intensity, respectively;  $r$ ,  $a_0$ , and  $\beta$  are the free parameters  
215 of the model.

The parameters are estimated by fitting the model using non-linear least-squares optimization solved with Levenberg-Marcquardt.

#### 2.4.4. Semi-quantitative analysis

The semi-quantitative analysis of the DCE-MRI is equivalent to extract  
 220 curve characteristics directly from the signal without a strict theoretical pharmacokinetic meaning. In this work, we use the model presented by Huisman et al. (2001) which formulate the MRI signal as in Eq. (13):

$$s(t) = \begin{cases} S_0 & 0 \leq t \leq t_0 \\ S_M - (S_M - S_0) \exp\left(\frac{-(t-t_0)}{\tau}\right) & t_0 < t \leq t_0 + 2\tau \\ S_M - (S_M - S_0) \exp\left(\frac{-(t-t_0)}{\tau}\right) + w(t - t_0 + 2\tau) & t > t_0 + 2\tau \end{cases} \quad (13)$$

where  $s(t)$  is the MRI signal intensity,  $S_0$  is the pre-contrast signal intensity,  $t_0$  is the time corresponding to the start of enhancement,  $S_M$  and  $\tau$  is the maximum  
 225 of the signal and the exponential time constant, and  $w$  is the slope of the linear part.

Huisman et al. argue that curve fitting via least-squares minimization using Nelder-Mead algorithm leads to inaccurate estimation of the free parameters: mainly the issue come from an incorrect estimation of the start of enhancement  
 230  $t_0$  leading to incorrect estimation of the other parameters. Therefore, they propose to: (i) estimate robustly  $t_0$ , (ii) estimate  $S_0$  by averaging the samples between 0 and  $t_0$  (ii) estimate  $w$  depending if the slope is significant or not, (iii) estimate  $S_M$  which should be the point at the intersection of the most probable slope line and the plateau.

235 Instead of these successive estimations, we propose a unified optimization in which  $t_0$  is fixed since that this is a key parameter. Therefore,  $t_0$  is robustly estimated from the AIF signal since that this is the most enhanced signal in which the start of enhancement is easily identifiable. The AIF signal is computed as in Section 2.4.2.  $t_0$  is estimated by finding the maximum in the beginning  
 240 of the first derivative of the MRI signal. Then, the function in Eq. (13) is fitted using non-linear least squares with Trust Region Reflective algorithm. Furthermore, the parameters  $\tau$  and  $S_M$  are bounded during the optimization to

ensure robust estimations.

From Eq. (13), the following features are extracted: (i) the wash-in corresponding to the slope between  $t_0$  and  $t_0 + 2\tau$ , (ii) the wash-out corresponding to the parameter  $w$ , (iii) the area under the curve between  $t_0$  and the end of the signal, (iv) the exponential time constant  $\tau$ , and (v) the relative enhancement  $S_M - S_0$ .

### 3. Experiments and results

#### 3.1. Classification of individual parameter for each model

The first experiment consists in comparing the classification performance using each individual parameter for the different models, to assess the potential benefit of the normalization method. Therefore, each feature is individually classified using a Gaussian Naive Bayes (NB) classifier in a Leave-One-Patient-Out Cross-Validation (LOPO CV) fashion. NB is used due to its simplicity and it enables to check the fitted parameters for interpretation. The results are summarized in Table 1. It can be noted that in the majority of the cases, normalizing the data improve the classification performance in terms of Area Under the Curve (AUC). Only the PUN model does not follow this tendency which might due to the fact that the function do not fit the data as good as the other model - WE WILL NEED SOME RMSE FOR EACH FITTING IF WE SAY SO..

It could be interesting to check the value of the mean and std of the NB. We could compute a ratio which refer to the class separability.

#### 3.2. Classification by combining the parameters for each model

Usually, the parameters are combined to form a multi-dimensional prior to classify the data. Therefore, for each model, all parameters are combined and classified using a Random Forest (RF) classifier in a LOPO CV fashion. The use of RF is motivated since that it leads to the best performance in the state-of-the-art methods (Litjens et al., 2014). The results are summarized by making

Table 1: AUC for each individual pharmacokinetic parameter using a NB classifier.

Features	Un-normalized data	Normalized data
<b>Brix model</b>		
$A$	0.62	0.67
$k_{el}$	0.52	0.61
$k_{ep}$	0.52	0.58
<b>Hoffmann model</b>		
$A$	0.50	0.56
$k_{el}$	0.53	0.64
$k_{ep}$	0.50	0.66
<b>Tofts model with population AIF</b>		
$K_{trans}$	0.62	0.65
$v_e$	0.50	0.52
$v_p$	0.63	0.53
<b>Tofts model with patient AIF</b>		
$K_{trans}$	0.66	0.65
$v_e$	0.50	0.52
$v_p$	0.37	0.65
<b>PUN model</b>		
$a_0$	0.53	0.51
$r$	0.59	0.55
$\beta$	0.56	0.44
<b>Semi-quantitative analysis</b>		
wash-in	0.64	0.51
wash-out	0.50	0.66
IAUC	0.61	0.64
$\tau$	0.57	0.61
$S_M - S_0$	0.63	0.64




Figure 5: ROC analysis using a RF classifier with and without normalization DCE-MRI data for different pharmacokinetic models.

Receiver Operating Characteristic (ROC) analysis and computing the AUC, as reported in Fig. 5. It can be noted that in all the cases the normalization of the data improve the classification performance.

### 3.3. Classification of the entire enhanced DCE-MRI signal

275 The quantification methods are extracting a minimal set of parameters which should characterized the enhancement DCE-MRI curves. However, this extraction could discard some information of the signal. This experiment attends to use the whole DCE-MRI signal to perform the classification. Therefore, the enhanced signal is classified using a RF classifier in a LOPO CV fashion. The

280 ROC analysis and AUC are reported in Fig. 6. It can be note that the worst performance are achieved while data without normalization. However, normalizing the data, this classification strategy lead the best classification performance, outperforming any quantification method, showing the importance of our normalization algorithm.




Figure 6: ROC analysis using the entire DCE-MRI signal with and without normalization in conjunction with a RF classifier.

#### 285 4. Discussions

#### 5. Conclusions and future works

#### Appendix A. Conversion from FLASH signal to media concentration

In this appendix, we show the demonstration used to extract the agent concentration from the MRI signal.

290 The signal equation in FLASH sequence (Haase et al., 1986) is defined as:

$$s(t) = S_{eq} \sin \alpha \cdot \frac{1 - \exp(-TR(R_{10} + r_1 c(t)))}{1 - \cos \alpha \cdot \exp(-TR(R_{10} + r_1 c(t)))}, \quad (\text{A.1})$$

where  $s(t)$  is the MRI signal,  $S_{eq}$  is the maximum signal amplitude of the spoiled gradient at the Echo Time (TE) which is proportional to the Proton Density (PD),  $\alpha$  is the flip angle,  $TR$  is the Repetition Time (TR),  $R_{10}$  is the pre-contrast tissue relaxation time also equal to  $\frac{1}{T_{10}}$ ,  $r_1$  is the relaxivity coefficient  
 295 of the contrast agent, and  $c(t)$  is the media concentration.

Therefore, the pre-contrast signal prior to bolus injection of the media is



defined as:

$$S_0 = S_{eq} \sin \alpha \cdot \frac{1 - \exp(-TR \cdot R_{10})}{1 - \cos \alpha \cdot \exp(-TR \cdot R_{10})}. \quad (\text{A.2})$$

To simplify the demonstration, let us define:

$$A = \exp(-TR \cdot R_{10}), \quad (\text{A.3})$$

$$B = \exp(-TR \cdot r_1 c(t)). \quad (\text{A.4})$$

Let us define:

$$S^* = \frac{S_0}{S_{eq} \sin \alpha}, \quad (\text{A.5})$$

$$= \frac{1 - A}{1 - A \cos \alpha}. \quad (\text{A.6})$$

300

Thus,

$$S^* \frac{s(t)}{S_0} = \frac{S_0}{S_{eq} \sin \alpha} \frac{s(t)}{S_0}, \quad (\text{A.7})$$

$$= \frac{1 - AB}{1 - AB \cos \alpha}. \quad (\text{A.8})$$

Now, let us define:

$$\frac{1 - \cos \alpha \cdot S^* \frac{s(t)}{S_0}}{1 - S^* \frac{s(t)}{S_0}} = \frac{1 - \cos \alpha \left( \frac{1 - AB}{1 - AB \cos \alpha} \right)}{1 - \frac{1 - AB}{1 - AB \cos \alpha}}, \quad (\text{A.9})$$

$$= \frac{1 - AB \cos \alpha - \cos \alpha (1 - AB)}{1 - AB \cos \alpha - (1 - AB)}, \quad (\text{A.10})$$

$$= \frac{1 - AB \cos \alpha - \cos \alpha + AB \cos \alpha}{1 - AB \cos \alpha - 1 + AB}, \quad (\text{A.11})$$

$$= \frac{1 - \cos \alpha}{AB(1 - \cos \alpha)}, \quad (\text{A.12})$$

$$= \frac{1}{AB}. \quad (\text{A.13})$$

Thus,

$$-TR \cdot R_{10} - TR \cdot r_1 c(t) = \ln \left( \frac{1 - \cos \alpha \cdot S^* \frac{s(t)}{S_0}}{1 - S^* \frac{s(t)}{S_0}} \right). \quad (\text{A.14})$$

Therefore,

$$c(t) = \frac{1}{TR \cdot r_1} \ln \left( \frac{1 - \cos \alpha \cdot S^* \frac{s(t)}{S_0}}{1 - S^* \frac{s(t)}{S_0}} \right) - \frac{R_{10}}{r_1}. \quad (\text{A.15})$$

## References

- 305 Brix, G., Semmler, W., Port, R., Schad, L.R., Layer, G., Lorenz, W.J., 1991. Pharmacokinetic parameters in cns gd-dtpa enhanced mr imaging. *Journal of computer assisted tomography* 15, 621–628.
- Carr, J.C., Carroll, T.J., 2011. *Magnetic resonance angiography: principles and applications*. Springer Science & Business Media.
- 310 Chen, J., Yao, J., Thomasson, D., 2008. Automatic determination of arterial input function for dynamic contrast enhanced mri in tumor assessment, in: *International Conference on Medical Image Computing and Computer-Assisted Intervention*, Springer. pp. 594–601. doi:10.1007/978-3-540-85988-8\_71.
- De Bazelaire, C.M., Duhamel, G.D., Rofsky, N.M., Alsop, D.C., 2004. Mr  
315 imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 t: preliminary results 1. *Radiology* 230, 652–659. doi:10.1148/radiol.2303021331.
- Fennessy, F.M., Fedorov, A., Penzkofer, T., Kim, K.W., Hirsch, M.S., Vangel, M.G., Masry, P., Flood, T.A., Chang, M.C., Tempany, C.M., et al., 2015.  
320 Quantitative pharmacokinetic analysis of prostate cancer dce-mri at 3t: comparison of two arterial input functions on cancer detection with digitized whole mount histopathological validation. *Magnetic resonance imaging* 33, 886–894. doi:10.1016/j.mri.2015.02.008.

- 325 Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., Parkin, D.M., 2010. Estimates of worldwide burden of cancer in 2008: Globocan 2008. *International journal of cancer* 127, 2893–2917. doi:10.1002/ijc.25516.
- Giannini, V., Mazzetti, S., Vignati, A., Russo, F., Bollito, E., Porphiglia, F., Stasi, M., Regge, D., 2015. A fully automatic computer aided diagnosis system for peripheral zone prostate cancer detection using multi-parametric magnetic resonance imaging. *Computerized Medical Imaging and Graphics* 46, 219–226. 330 doi:10.1016/j.compmedimag.2015.09.001.
- Glozzi, A., Mazzetti, S., Delsanto, P.P., Regge, D., Stasi, M., 2011. Phenomenological universalities: a novel tool for the analysis of dynamic contrast enhancement in magnetic resonance imaging. *Physics in medicine and biology* 335 56, 573.
- Haase, A., Frahm, J., Matthaei, D., Hanicke, W., Merboldt, K.D., 1986. Flash imaging. rapid nmr imaging using low flip-angle pulses. *Journal of Magnetic Resonance* (1969) 67, 258–266. doi:10.1016/0022-2364(86)90433-6.
- Heilmann, M., Kiessling, F., Enderlin, M., Schad, L.R., 2006. Determination of pharmacokinetic parameters in dce mri: consequence of nonlinearity between 340 contrast agent concentration and signal intensity. *Investigative radiology* 41, 536–543. doi:10.1097/01.rli.0000209607.99200.53.
- Hoffmann, U., Brix, G., Knopp, M.V., Heß, T., Lorenz, W.J., 1995. Pharmacokinetic mapping of the breast: a new method for dynamic mr mammography. *Magnetic resonance in medicine* 33, 506–514. doi:10.1002/mrm. 345 1910330408.
- Huisman, H.J., Engelbrecht, M.R., Barentsz, J.O., 2001. Accurate estimation of pharmacokinetic contrast-enhanced dynamic mri parameters of the prostate. *Journal of Magnetic Resonance Imaging* 13, 607–614. doi:10.1002/jmri. 350 1085.
- Ibanez, L., Schroeder, W., Ng, L., Cates, J., 2005. The itk software guide .

- Lemaitre, G., Dastjerdi, M.R., Massich, J., Vilanova, J.C., Walker, P.M., Freixenet, J., Meyer-Baese, A., Mériaudeau, F., Marti, R., 2016. Normalization of t2w-mri prostate images using rician a priori, in: SPIE Medical Imaging, International Society for Optics and Photonics. pp. 978529–978529. doi:10.1117/12.2216072.
- Lemaître, G., Martí, R., Freixenet, J., Vilanova, J.C., Walker, P.M., Meriaudeau, F., 2015. Computer-aided detection and diagnosis for prostate cancer based on mono and multi-parametric mri: A review. *Computers in biology and medicine* 60, 8–31. doi:10.1016/j.combiomed.2015.02.009.
- Litjens, G., Debats, O., Barentsz, J., Karssemeijer, N., Huisman, H., 2014. Computer-aided detection of prostate cancer in mri. *IEEE transactions on medical imaging* 33, 1083–1092. doi:10.1109/TMI.2014.2303821.
- Meng, R., Chang, S.D., Jones, E.C., Goldenberg, S.L., Kozlowski, P., 2010. Comparison between population average and experimentally measured arterial input function in predicting biopsy results in prostate cancer. *Academic radiology* 17, 520–525. doi:10.1016/j.acra.2009.11.006.
- Parker, G.J., Roberts, C., Macdonald, A., Buonaccorsi, G.A., Cheung, S., Buckley, D.L., Jackson, A., Watson, Y., Davies, K., Jayson, G.C., 2006. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced mri. *Magnetic resonance in medicine* 56, 993–1000. doi:10.1002/mrm.21066.
- Schabel, M.C., Parker, D.L., 2008. Uncertainty and bias in contrast concentration measurements using spoiled gradient echo pulse sequences. *Physics in medicine and biology* 53, 2345. doi:10.1088/0031-9155/53/9/010.
- Shanbhag, D., Gupta, S.N., Rajamani, K., Zhu, Y., Mullick, R., 2012. A generalized methodology for detection of vascular input function with dynamic contrast enhanced perfusion data, in: ISMRM, p. 10.

- Tofts, P.S., Berkowitz, B., Schnall, M.D., 1995. Quantitative analysis of dynamic  
gd-dtpa enhancement in breast tumors using a permeability model. *Magnetic*  
380 *Resonance in Medicine* 33, 564–568. doi:10.1002/mrm.1910330416.
- Weinreb, J.C., Barentsz, J.O., Choyke, P.L., Cornud, F., Haider, M.A., Macura,  
K.J., Margolis, D., Schnall, M.D., Shtern, F., Tempany, C.M., et al., 2016. Pi-  
rads prostate imaging-reporting and data system: 2015, version 2. *European*  
385 *urology* 69, 16–40.
- Zhu, Y., Chang, M.C., Gupta, S., 2011. Automated determination of arte-  
rial input function for dce-mri of the prostate, in: *SPIE Medical Imag-  
ing, International Society for Optics and Photonics*. pp. 79630W–79630W.  
doi:10.1117/12.878213.